Literature DB >> 2017632

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989.

A Fenoll1, C Martín Bourgon, R Muñóz, D Vicioso, J Casal.   

Abstract

Serotypes and antibiotic susceptibilities were determined for 2,197 Streptococcus pneumoniae strains isolated from patients with systemic infections over an 11-year period. The predominant serogroups and serotypes, in order of decreasing frequency, were 3, 6, 23, 19, 9, 1, 5, 8, 7, 14, 4, and 15; these types accounted for more than 75% of the strains studied. Altogether, 93% of the pneumococci belonged to groups or types included in the 23-valent pneumococcal vaccine. Overall, 65.5% of pneumococci were resistant to one or more drugs. The incidence of penicillin-resistant pneumococci rose from 6% in 1979 to 44% in 1989, and the degree of penicillin resistance also increased throughout the study. Overall, the resistance rates were 28% for penicillin, 56% for tetracycline, 43% for chloramphenicol, and 5% for erythromycin. Seventy-one pneumococcal isolates resistant to all four antibiotics tested were found. The prevalence of pneumococcal resistance in Spain is, as far as we know, among the highest published to date.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2017632     DOI: 10.1093/clinids/13.1.56

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  56 in total

1.  Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network.

Authors:  L McGee; L McDougal; J Zhou; B G Spratt; F C Tenover; R George; R Hakenbeck; W Hryniewicz; J C Lefévre; A Tomasz; K P Klugman
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

2.  Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008.

Authors:  A Fenoll; L Aguilar; M D Vicioso; M J Gimenez; O Robledo; J J Granizo; C Mendez
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 3.  Diagnosis and treatment of bacterial meningitis.

Authors:  H El Bashir; M Laundy; R Booy
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

4.  Penicillin-resistant pneumococcus in community-acquired bacteremic pneumonia in Germany.

Authors:  R R Reinert; A Kaufhold; H Kierdorf
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

5.  Activity of vancomycin, teicoplanin and cephalosporins against penicillin-susceptible and penicillin-intermediate Streptococcus pneumoniae.

Authors:  V G Loo; J Lavallée; D McAlear; H G Robson
Journal:  Can J Infect Dis       Date:  1995-03

6.  Multiplex PCR to determine Streptococcus pneumoniae serotypes causing otitis media in the Republic of Ireland with further characterisation of antimicrobial susceptibilities and genotypes.

Authors:  I Vickers; D O'Flanagan; M Cafferkey; H Humphreys
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-13       Impact factor: 3.267

7.  Meningoencephalitis due to penicillin-resistant Streptococcus pneumoniae.

Authors:  T Vassal; O Piot; Z Mallat; D Lesage; B Guidet; G Offenstadt
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 8.  Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996).

Authors:  A Fenoll; I Jado; D Vicioso; A Pérez; J Casal
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

9.  In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.

Authors:  R R Reinert; A Bryskier; R Lütticken
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia.

Authors:  C Cabellos; J Ariza; B Barreiro; F Tubau; J Liñares; R Pallarés; F Manresa; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.